Table 2.

Effects of treatment with armodafinil on behaviors associated with ADHD.

Study Type	Treatment	Pathology	Effect	References
Double-blind, placebo-controlled, crossover study	Armodafinil unique dose (250 mg)	Multiple Sclerosis	Improves delayed verbal recall in 17 patients with Multiple Sclerosis	[66]
Randomized, double-blind, placebo-controlled trial	Armodafinil 6 weeks (250 mg/day)	Schizophrenia or schizoaffective disorder	Improved anhedonia-asociality in 60 patients with schizophrenia or schizoaffective disorder	[73]
Pilot trial	Armodafinil 12 weeks (125-250 mg/day)	Dementia with Lewy bodies	Improvements in hypersomnia and wakefulness in 20 patients with Dementia with Lewy Bodies	[74]
Randomized, placebo-controlled, double-blind trial followed by open-label extension.	Armodafinil 12 weeks (50-250 mg/day)	Mild to moderate closed traumatic brain injury	Significantly improved sleep latency in 88 patients with excessive sleepiness associated with mild to moderate traumatic brain injury	[75]